Sana Biotechnology Inc
$ 3.29
-4.36%
24 Apr - close price
- Market Cap 888,273,000 USD
- Current Price $ 3.29
- High / Low $ 3.47 / 3.24
- Stock P/E N/A
- Book Value 0.60
- EPS -0.96
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -1.19 %
- 52 Week High 6.55
- 52 Week Low 1.60
About
Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
Analyst Target Price
$8.57
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-24 | 2025-11-06 | 2025-08-11 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-02-29 | 2023-11-08 | 2023-08-03 | 2023-05-08 |
| Reported EPS | -0.16 | -0.16 | -0.39 | -0.2 | -0.23 | -0.25 | -0.32 | -0.32 | -0.41 | 0.02 | -0.59 | -0.43 |
| Estimated EPS | -0.1444 | -0.18 | -0.2 | -0.2 | -0.2428 | -0.27 | -0.28 | -0.32 | -0.38 | -0.45 | -0.43 | -0.45 |
| Surprise | -0.0156 | 0.02 | -0.19 | 0 | 0.0128 | 0.02 | -0.04 | 0 | -0.03 | 0.47 | -0.16 | 0.02 |
| Surprise Percentage | -10.8033% | 11.1111% | -95% | 0% | 5.2718% | 7.4074% | -14.2857% | 0% | -7.8947% | 104.4444% | -37.2093% | 4.4444% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.15 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SANA
2026-04-25 06:09:09
Wall Street Zen has downgraded Sana Biotechnology (NASDAQ:SANA) from a "sell" to a "strong sell," despite MarketBeat's consensus remaining a "Moderate Buy" with an average price target of $8.20. SANA shares experienced a 4.4% dip, opening at $3.29, after the company missed its Q1 EPS estimates, reporting ($0.16) versus a consensus of ($0.13). The clinical-stage biotech, focusing on engineered cell therapies, has seen varied analyst ratings, including upgrades from Wedbush and Bank of America, but also downgrades from Zacks Research and HC Wainwright.
2026-04-24 10:40:04
This article provides definitive information statements (DEF 14A) for Sana Biotechnology. The content explicitly states "Document," indicating that the document itself contains further details regarding these statements.
2026-04-24 10:39:21
This article is a DEFA14A filing from Sana Biotechnology, indicating a document submission related to proxy materials. The content provided is simply "Document", suggesting the main filing details are within the attached document.
2026-04-24 10:39:21
Sana Biotechnology (NASDAQ:SANA) reclassified board member Steven D. Harr, M.D., to balance its three director classes, ensuring an equal distribution of three directors per class. This governance change, made to comply with the company's certificate of incorporation, maintains Dr. Harr's continuous service despite the reclassification from a Class I to a Class III director. The company, valued at $944 million, has seen significant stock performance and is also progressing with its SC451 pancreatic islet cell therapy through a collaboration with the Mayo Clinic.
2026-04-24 10:39:21
Sana Biotechnology (SANA) rebalanced its Board of Directors on April 22, 2026, by reclassifying Director Steven D. Harr from a Class I to a Class III director. This administrative change ensures an equal distribution of directors across the three classes, aligning with the company's governance structure, and did not interrupt Dr. Harr's board service. Analysts currently rate SANA as a Buy with a $7.00 price target, though Spark's AI Analyst gives a Neutral rating due to weak financial fundamentals despite constructive corporate events.
2026-04-24 10:39:21
Sana Biotechnology, Inc. (SANA) has released details for its virtual 2026 annual stockholder meeting, scheduled for June 4, 2026. Stockholders will vote on the re-election of three Class II directors—Hans E. Bishop, Robert Nelsen, and Alise S. Reicin, M.D.—and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The Board unanimously recommends voting "FOR" all proposals.
